- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
HLS Therapeutics Inc (HLS)
HLS Therapeutics Inc stock price live, this page displays TSX HLS stock exchange data. View the HLS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the HLS Therapeutics Inc real time stock price chart below.
What Is the HLS Therapeutics Inc Stock Price Today?
The HLS Therapeutics Inc stock price today is 4.88.
What Is the Stock Symbol for HLS Therapeutics Inc?
The stock symbol for HLS Therapeutics Inc is ""HLS.""
What Stock Exchange Does HLS Therapeutics Inc Trade On?
HLS Therapeutics Inc is listed and trades on the Toronto stock exchange.
Is HLS Therapeutics Inc a Good Stock to Buy?
Determining whether HLS Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HLS quote. (ISIN: CA40390B1094)
What Is the HLS Therapeutics Inc Stock Price Today?
The HLS Therapeutics Inc stock price today is 4.88.
What Is the Stock Symbol for HLS Therapeutics Inc?
The stock symbol for HLS Therapeutics Inc is ""HLS.""
What Stock Exchange Does HLS Therapeutics Inc Trade On?
HLS Therapeutics Inc is listed and trades on the Toronto stock exchange.
Is HLS Therapeutics Inc a Good Stock to Buy?
Determining whether HLS Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HLS quote. (ISIN: CA40390B1094)
Toronto
Currency in CAD
4.88
-0.06(-1.21%)
Closed·
Fair Value
An estimate of a HLS Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.88
4.97
52 wk Range
3.00
5.23
HLS Scorecard
Full Analysis
High shareholder yield
Earnings results expected in 12 days
More Info
Fair Value
An estimate of a HLS Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.884.97
52 wk Range
3.005.23
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
HLS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a HLS Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
6.27
Upside
+28.39%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Valuation implies a strong free cash flow yield
- HLS Therapeutics receives Investment Bank Analyst Rating Update
- Investing.com
Pro - HLS Therapeutics receives Investment Bank Analyst Rating Update
- Investing.com
Pro - HLS Therapeutics receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- HLS Therapeutics receives Investment Bank Analyst Rating Update
- Investing.com
Pro - HLS Therapeutics receives Investment Bank Analyst Rating Update
- Investing.com
Pro - HLS Therapeutics receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
HLS Therapeutics Inc Company Profile
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders, central nervous system, and cardiovascular disease in Canada, the United States, and internationally. The company’s lead products include Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds royalty interest in Takeda’s Obizur, which is a porcine recombinant Factor VIII for acquired Hemophilia A. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
HLS Therapeutics Inc Earnings Call Summary for Q1/2025
- Q1 2025 EPS beat at -$0.1016 vs -$0.123 forecast; revenue missed at $9.16M vs $12.4M expected. Stock stable at $4.49.
- Total revenue up 1% YoY to $12.6M. Canadian product sales grew 13%. Adjusted EBITDA surged 41% excluding royalties.
- Cash from operations rose to $3.5M from $800K in Q1 2024. Net debt reduced to $46.7M, improving financial health.
- Vascepa net sales projected to grow 186% in 2025. Nexletol and Nexlazette launch planned for early 2026.
- Adjusted EBITDA growth forecast between 17-23%. CEO highlights revenue growth alongside increased profitability.
Last Updated: 08/05/2025, 14:38
Read Full TranscriptCompare HLS to Peers and Sector
Metrics to compare | HLS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHLSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.3x | −0.4x | −0.5x | |
PEG Ratio | −0.18 | 0.00 | 0.00 | |
Price/Book | 1.7x | 0.5x | 2.6x | |
Price / LTM Sales | 2.0x | 1.7x | 3.2x | |
Upside (Analyst Target) | 0.0% | 27.9% | 41.7% | |
Fair Value Upside | Unlock | 13.5% | 6.1% | Unlock |
Analyst Ratings
2 Buy
3 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 6.27
(+28.39% Upside)
Earnings
Latest Release
May 08, 2025
EPS / Forecast
-0.14 / -0.123
Revenue / Forecast
12.62M / 12.40M
FAQ
What Stock Exchange Does HLS Therapeutics Trade On?
HLS Therapeutics is listed and trades on the Toronto Stock Exchange stock exchange.
What Is the Stock Symbol for HLS Therapeutics?
The stock symbol for HLS Therapeutics is "HLS."
What Is the HLS Therapeutics Market Cap?
As of today, HLS Therapeutics market cap is 154.00M.
What Is HLS Therapeutics's Earnings Per Share (TTM)?
The HLS Therapeutics EPS (TTM) is -0.57.
When Is the Next HLS Therapeutics Earnings Date?
HLS Therapeutics will release its next earnings report on 06 Aug 2025.
From a Technical Analysis Perspective, Is HLS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has HLS Therapeutics Stock Split?
HLS Therapeutics has split 0 times.
How Many Employees Does HLS Therapeutics Have?
HLS Therapeutics has 92 employees.
What is the current trading status of HLS Therapeutics (HLS)?
As of 26 Jul 2025, HLS Therapeutics (HLS) is trading at a price of 4.88, with a previous close of 4.94. The stock has fluctuated within a day range of 4.88 to 4.97, while its 52-week range spans from 3.00 to 5.23.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.